GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Cash Flow from Investing

Cosmo Pharmaceuticals NV (XSWX:COPN) Cash Flow from Investing : CHF-87.3 Mil (TTM As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Jun. 2023, Cosmo Pharmaceuticals NV spent CHF1.4 Mil on purchasing property, plant, equipment. It gained CHF0.0 Mil from selling property, plant, and equipment. It spent CHF0.0 Mil on purchasing business. It gained CHF0.0 Mil from selling business. It spent CHF62.1 Mil on purchasing investments. It gained CHF15.2 Mil from selling investments. It paid CHF5.8Mil for net Intangibles purchase and sale. And it paid CHF0.8 Mil for other investing activities. In all, Cosmo Pharmaceuticals NV spent CHF54.9 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Jun. 2023.


Cosmo Pharmaceuticals NV Cash Flow from Investing Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Cash Flow from Investing Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.00 -53.16 81.54 25.87 1.67

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.02 26.84 35.44 -32.43 -54.87

Cosmo Pharmaceuticals NV Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Cosmo Pharmaceuticals NV's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Cosmo Pharmaceuticals NV's Cash Flow from Investing for the quarter that ended in Jun. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-87.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV  (XSWX:COPN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Cosmo Pharmaceuticals NV's purchase of property, plant, equipment for the six months ended in Jun. 2023 was CHF-1.4 Mil. It means Cosmo Pharmaceuticals NV spent CHF1.4 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Cosmo Pharmaceuticals NV's sale of property, plant, equipment for the six months ended in Jun. 2023 was CHF0.0 Mil. It means Cosmo Pharmaceuticals NV gained CHF0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Cosmo Pharmaceuticals NV's purchase of business for the six months ended in Jun. 2023 was CHF0.0 Mil. It means Cosmo Pharmaceuticals NV spent CHF0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Cosmo Pharmaceuticals NV's sale of business for the six months ended in Jun. 2023 was CHF0.0 Mil. It means Cosmo Pharmaceuticals NV gained CHF0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Cosmo Pharmaceuticals NV's purchase of investment for the six months ended in Jun. 2023 was CHF-62.1 Mil. It means Cosmo Pharmaceuticals NV spent {stock_data.stock.currency_symbol}}62.1 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Cosmo Pharmaceuticals NV's sale of investment for the six months ended in Jun. 2023 was CHF15.2 Mil. It means Cosmo Pharmaceuticals NV gained CHF15.2 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Cosmo Pharmaceuticals NV's net Intangibles purchase and sale for the six months ended in Jun. 2023 was CHF-5.8 Mil. It means Cosmo Pharmaceuticals NV paid CHF5.8 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cosmo Pharmaceuticals NV's cash from discontinued investing activities for the six months ended in Jun. 2023 was 0.0 Mil. It means Cosmo Pharmaceuticals NV paid CHF0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cosmo Pharmaceuticals NV's cash from other investing activities for the six months ended in Jun. 2023 was CHF-0.8 Mil. It means Cosmo Pharmaceuticals NV paid CHF0.8 Mil for other investing activities.


Cosmo Pharmaceuticals NV Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines